Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
65actual
Sites
14
Countries
Australia, Denmark, Spain +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Why the sponsor stopped it
Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-15 | actual | When the study began enrolling |
| Primary completion | 2023-10-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2023-10-23 | actual | The whole study's end, after follow-up |
| First posted | 2020-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: Acapatamab — also filed as PSMA targeted therapy
- Drug: Enzalutamide — also filed as Androgen receptor inhibitor
- Drug: Abiraterone — also filed as Cytochrome P450 (CYP)17 inhibitor
- Drug: AMG 404 — also filed as PD-1 inhibitor
Primary outcomes
what the primary-completion date above is the date OFDose exploration only: Number of participants who experience dose limiting toxicities (DLTs)
measured Up to 3 years
Number of participants who experience one or more treatment-emergent adverse events (TEAEs)
measured Up to 3 years
Number of participants who experience one or more treatment-related adverse events
measured Up to 3 years
Number of participants who experience a clinically significant change in vital signs
measured Up to 3 years
Number of participants who experience a clinically significant change in clinical laboratory tests
measured Up to 3 years
Related
AMGN · their whole pipeline · Castration-Resistant Prostate Cancer readouts · Congress trades in AMGN · Executive-branch trades in AMGN
AMGN's other studiesmost recently updated first
- A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) Phase 2 · Completed
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration Phase 3 · Recruiting
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Phase 3 · Recruiting
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Phase 3 · Recruiting
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 1 · Recruiting
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed